Unconventional anticancer agents: A systematic review of clinical trials

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 136-140

  Vickers, Andrew J ^a   Kuo, Joyce ^a   Cassileth, Barrie R ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANTINEOPLASTIC AGENT; ARGININE; CURCUMIN; DIMETHYL SULFOXIDE; GREEN TEA EXTRACT; HYDRAZINE SULFATE; KRESTIN; LAETRILE; LENTINAN; MELATONIN; VISCUM ALBUM EXTRACT;

ALTERNATIVE MEDICINE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PUBLICATION; SYSTEMATIC REVIEW; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; NEOPLASMS;

EID: 33644833376     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8406     Document Type: Article

References (15)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. US Congress Office of Technology Assessment: Unconventional Cancer Treatments. Washington, DC, US Congress, report No. OTA-H-405, 1990
3. Nio Y, Tsubono M, Tseng CC, et al: Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 4:117-128, 1992
4. Small EJ, Frohlich MW, Bok R, et al: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595-3603, 2000
5. US Food and Drug Administration: 2002 Safety Alerts for Drugs, Biologies, Medical Devices, and Dietary Supplements: PC SPES, SPES (BotanicLab). http://www.fda.gov/medwatch/SAFETY/2002/safety02.htm#spes
6. Sun AS, Ostadal O, Ryznar V, et al: Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer 34:62-69, 1999
7. Pfeifer BL, Pirani JF, Hamann SR, et al: PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 85:481-485, 2000
8. Pisters KM, Newman RA, Coldman B, et al: Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19:1830-1838, 2001
9. Creagan ET, Moertel CG, O'Fallon JR, et al: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: A controlled trial. N Engl J Med 301:687-690, 1979
10. Pauling L: Vitamin C therapy of advanced cancer. N Engl J Med 302:694-695, 1980
11. Moertel CG, Fleming TR, Creagan ET, et al: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: A randomized double-blind comparison. N Engl J Med 312:137-141, 1985
12. Padayatty SJ, Levine M: New insights into the physiology and pharmacology of vitamin C. CMAJ 164:353-355, 2001
13. Loprinzi CL, Levitt R, Barton DL, et al: Evaluation of shark cartilage in patients with advanced cancer: A North Central Cancer Treatment Group trial. Cancer 104:176-182, 2005
14. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
15. Fox E, Curt GA, Balis FM: Clinical trial design for target-based therapy. Oncologist 7:401-409, 2002